EGS Healthcare Capital Partners is a specialist private equity firm focused on investments in the healthcare sector. Specific areas of interest include biotechnology, specialty pharmaceutical, and medical device companies. EGS typically invests in late-stage private and emerging public companies with promising products. EGS prefers to lead investments with an initial commitment of $5 million per transaction. The Firm generally seeks board representation. EGS Healthcare Partner was formed in 1999 and is based in Rowayton, Connecticut.
Join Mergr to view the latest updates and news from Rowayton-based EGS Healthcare Capital Partners.
EGS Healthcare Capital Partners’ most common sectors for investment are medical products (58%) and life science (43%). The Firm’s most common investment types include venture (72%) and buyout (lbo, mbo, mbi) (15%). In total, EGS Healthcare Capital Partners has invested in 4 US states and 2 different countries. Its largest (disclosed) acquisition occurred in 2003 when it acquired Ardais for $34M.
The Firm’s most common exit type is trade sale (50%). EGS Healthcare Capital Partners’ largest (disclosed) exit occurred in 2012 when it sold Amylin Pharmaceuticals for $5.3B.
Join Mergr to view EGS Healthcare Capital Partners’ full profile and discover more small private equity firms just like it.
No obligation. Cancel anytime.